Search This Blog

Wednesday, August 6, 2025

Congress Looks to Ease Restrictions on Veterans' Use of Non-VA Clinics and Hospitals

 John-Paul Sager appreciates the care he has received at Department of Veterans Affairs (VA) hospitals and clinics, but he thinks it should be easier for veterans like him to use their benefits elsewhere.

Sager, a Marine Corps and Army veteran, uses his VA coverage for non-VA treatment of back injuries stemming from his military service. But he said he sometimes must make several phone calls to obtain approval to see a local chiropractor. "It seems like it takes entirely too long," he said.

Many veterans live hours from VA facilities, or they need health services that aren't readily available from the VA. In such cases, the department is supposed to provide a referral and pay for private care. Critics say it often hesitates to do so.

Republicans controlling Congress aim to streamline the process of obtaining what is known as community care.

Two Republican senators have introduced legislationopens in a new tab or window that would make it easier for rural veterans to seek care at local hospitals and clinics. The proposals would build on VA community care programs that started under Democratic President Barack Obama and were expanded in Trump's first term.

Critics worry that steering veterans to private care facilities drains federal money from the VA hospital and clinic system. But supporters say veterans shouldn't be forced to travel long distances or wait months for the treatment they could obtain at local hospitals and clinics.

"My main concern is for veterans, not for the VA," Sen. Kevin Cramer (R-N.D.) told KFF Health News. "I don't believe we have an obligation to sustain the bureaucracy."

About 9 million veterans are enrolled in the VA health system. Last year, about 3 million of them -- including 1.2 million rural veterans -- used their benefits to cover care at non-VA facilities, according to data provided by the department.

Cramer co-sponsored a billopens in a new tab or window that would allow veterans who live within 35 miles of a rural, "critical access" hospital to use VA benefits to cover care there or at affiliated clinics without referrals from VA staff.

Cramer, who serves on the Senate Veterans' Affairs Committee, noted his state has just one VA hospital. It's in Fargo, on the state's eastern border, which is more than 400 miles by car from parts of western North Dakota.

Many North Dakota veterans drive past multiple community hospitals to get to the VA hospital for treatment, he said. Meanwhile, many rural hospitals are desperate for more patients and income. "I kept thinking to myself, 'This doesn't make any sense at all,'" Cramer said.

Cramer said previous laws, including the VA Mission Actopens in a new tab or window, made it easier for veterans to use their benefits to cover care at community hospitals and clinics.

But he said veterans still must fill out too much paperwork and obtain approval from VA staffers to use non-VA facilities.

"We can't let the VA itself determine whether a veteran is qualified to receive local care," he said.

U.S. Rep. Mark Takano of California, who is the top Democrat on the House Veterans' Affairs Committee, said he sees the need for outside care for some veterans. But he contends Republicans are going overboard in shifting the department's money to support private healthcare facilities.

The VA provides specialized care that responds to veterans' needs and experiences, he argues.

"We must prevent funds from being siphoned away from veterans' hospitals and clinics, or VA will crumble," Takano said in a statement released by his office. "Veterans cannot afford for us to dismantle VA direct care in favor of shifting more care to the community."

Some veterans' advocacy groups have also expressed concerns.

Jon Retzer, deputy national legislative director for the Disabled American Veterans, said the group wants to make it easier for veterans to find care. Rural and female veterans can have a particularly tough time finding appropriate, timely services at VA hospitals and clinics, he said. But the Disabled American Veterans doesn't want to see VA facilities weakened by having too much federal money diverted to private hospitals and clinics.

Retzer said it's true that patients sometimes wait for VA care, but so do patients at many private hospitals and clinics. Most delays stem from staff shortages, he said, which afflict many health facilities. "This is a national crisis."

Retzer said the Disabled American Veterans favors continuing to require referrals from VA physicians before veterans can seek VA-financed care elsewhere. "We want to ensure that the VA is the primary provider of that care," he said.

Veterans Affairs Secretary Doug Collins has pledgedopens in a new tab or window to improve the community care program while maintaining the strength of the department's hospitals and clinics. The department declined a KFF Health News request to interview Collins.

Marcus Lewis, CEO of First Care Health Center, which includes a hospital in Park River, North Dakota, supports Cramer's bill. Lewis is a Navy veteran who uses the VA's community care option to pay for treatment of a back injury stemming from his military service.

Overall, Lewis said, the community care program has become easier to use. But the application process remains complicated, and participants must repeatedly obtain VA referrals for treatment of chronic issues, he said. "It's frustrating."

Park River is a 1,400-person town about 50 miles south of the Canadian border. Its 14-bed hospital offers an array of services, including surgery, cancer care, and mental health treatment. But Lewis regularly sees a VA van picking up local veterans, some of whom travel 140 miles to Fargo for care they're entitled to receive locally.

"I think a lot of folks just don't want to fight the system," he said. "They don't want to go through the extra hoops, and so they'll jump in the van, and they'll ride along."

Rep. Mike Bost (R-Ill.), chairman of the House Veterans' Affairs Committee, said veterans in some areas of the country have had more trouble than others in getting VA approval for care from private clinics and hospitals.

Bost helped gain the House's approvalopens in a new tab or window for Trump's request for $34.7 billion for the community care program in 2026. Although spending on the program has gone up and down in recent years, the appropriation represents an increase of about 50% from what it was in 2025 and 2022. The Senate included similar figures for next year in its version of a military spending budget that passed Aug. 1.opens in a new tab or window

Bost also co-sponsored a House billopens in a new tab or window that would spell out requirements for the VA to pay for community care.

Sager hopes the new proposals make life easier for veterans. The Gulf War veteran lives in the northeastern Iowa town of Denver. He travels about 15 miles to Waterloo to see a chiropractor, who treats him for back and shoulder pain from injuries he suffered while training Saudi troops in hand-to-hand combat.

Sager, who remains active in the Army Reserve, also visits a Waterloo outpatient clinic run by the VA, where his primary care doctor practices. He appreciates the agency's mission, including its employment of many veterans. "You just feel like you're being taken care of by your own," he said.

He believes the VA can run a strong hospital and clinic system while offering alternatives for veterans who live far from those facilities or who need care the VA can't promptly provide.

The local VA doesn't offer chiropractic care, so it pays for Sager to visit the private clinic. But every few months, he needs to obtain fresh approval from the VA. That often requires several phone calls, he said.

Sager is one of about a dozen veterans who use the community care program to pay for visits at Vanderloo Chiropractic Clinic, office manager Linda Gill said.

Gill said the VA program pays about $34 for a typical visit, which is comparable to private insurance, but the paperwork is more burdensome. She said leaders of the chiropractic practice considered pulling out of the VA program but decided to put up with the hassles for a good cause. She wishes veterans didn't have to jump through so many hoops to obtain convenient care.

"After what they've done for us? Please," she said.

'KFF Health Newopens in a new tab or windowsopens in a new tab or window is a national newsroom that produces in-depth journalism about health issues and is one of the core operating programs at KFF '

https://www.medpagetoday.com/publichealthpolicy/militarymedicine/116859

Jazz's Modeyso becomes first FDA-approved drug for type of aggressive brain cancer

 When Jazz Pharmaceuticals' incoming CEO Renee Gala takes the reins at the drugmaker next week, she'll have a brand-new launch to manage.

Wednesday, the FDA approved Jazz's Modeyso (dordaviprone) for patients ages 1 and older with H3 K27M-mutant diffuse midline glioma who have progressive disease following prior therapy. The drug, picked up in the company's $935 million buyout of Chimerix earlier this year, is the first systemic therapy for those with the aggressive brain cancer.

The FDA granted the medicine accelerated approval based on results seen across 50 patients in five open-label, nonrandomized U.S. trials, the agency said in an Aug. 6 release. 

Among the evaluated patients, who were at least 90 days post radiation therapy, the overall response rate was 22% and the median duration of response was 10.3 months, according to the FDA.

The drug's label carries warnings for hypersensitivity, QTc interval prolongation and embryo-fetal toxicity, the FDA noted.

Jazz struck a $935 million deal for Chimerix back in March and closed the deal the following month.

In a December 2024 corporate presentation, Chimerix estimated there are about 2,000 patients who could potentially be eligible for dordaviprone in the U.S. Citing the potential for "ultra-orphan" pricing, the biotech said there could be a blockbuster market opportunity for its therapy. Before selling itself to Jazz, Chimerix had kicked off a phase 3 trial of its cancer med.

Meanwhile, Jazz has been working through a CEO change in 2025. Jazz's longtime CEO Bruce Cozadd announced his intention to retire in December, and the company revealed Gala as his successor in July. Gala, who's been with Jazz for five years, is set to start her new role on Monday.

https://www.fiercepharma.com/pharma/jazzs-modeyso-becomes-first-fda-approved-drug-type-aggressive-brain-cancer

OpenAI in Talks for Share Sale at $500 Billion Valuation

ChatGPT maker OpenAI is in early-stage discussions about a stock sale that would allow employees to cash out and could value the company at about $500 billion, a source familiar with the matter said.

That would represent an eye-popping bump-up from its current valuation of $300 billion, with the sale underscoring both OpenAI's rapid gains in users and revenue as well as the intense competition among artificial intelligence firms to secure talented workers.

The transaction, which would come before a potential IPO, would allow current and former employees to sell several billion dollars worth of shares, said the source, who requested anonymity because the talks are private.

Bolstered by its flagship product ChatGPT, OpenAI doubled its revenue in the first seven months of the year, reaching an annualized run rate of $12 billion, and is on track to reach $20 billion by year-end, the source added.

Microsoft-backed OpenAI has about 700 million weekly active users for its ChatGPT products, a surge from about 400 million in February.

The share sale talks come on the heels of OpenAI's primary funding round announced earlier this year, which aims to raise $40 billion, led by Japan's SoftBank Group.

SoftBank has until the end of the year to fund its $22.5 billion portion of the round, but the remainder has been subscribed at a valuation of $300 billion, the source said.

Tech giants are competing aggressively for AI talent with lucrative compensation packages. Meta is notably investing billions in Scale AI to poach its 28-year-old CEO, Alexandr Wang, so that he can lead its new super intelligence unit.

Unlisted firms such as ByteDance, Databricks and Ramp have also used private share sales to help update a company's valuation and reward long-term employees.

Existing investors in OpenAI, including Thrive Capital, are in discussions to participate in the employee share sale, the source said.

Thrive Capital declined to comment. Bloomberg first reported the potential sale.

OpenAI is working on a significant corporate restructuring that would move away from its current capped-profit model and open the door for an initial public offering in the future.

Chief Financial Officer Sarah Friar said in May, however, that an IPO would only come when the company and markets were ready.

https://finance.yahoo.com/news/openai-talks-share-sale-valuing-014446109.html

Geron Q2 2025 presentation: RYTELO sales climb 24%

 Geron Corporation (NASDAQ:GERN) presented its Q2 2025 earnings on August 6, 2025, reporting significant growth in RYTELO sales and progress in its clinical pipeline. The biotech company’s stock jumped 11.67% in premarket trading to $1.34, signaling investor confidence after previous quarters of share price pressure.

The presentation, led by Interim CEO Dawn Bir and incoming CEO Harout Semerjian, highlighted a 24% quarter-over-quarter increase in RYTELO sales, with the telomerase inhibitor gaining traction in the myelofibrosis treatment landscape.

Quarterly Performance Highlights

Geron reported Q2 2025 RYTELO net product revenue of $49.0 million, a substantial improvement from the $39.6 million reported in Q1 2025 that had previously disappointed analysts. The company highlighted several key performance metrics showing growing market penetration.

As shown in the following performance metrics chart:

The company reported approximately 17% demand increase in Q2 2025 compared to Q1, with around 1,000 ordering accounts since approval. Notably, about 400 new accounts were added year-to-date, suggesting accelerating adoption. Approximately 30% of new RYTELO patient starts are occurring in first and second line treatment, potentially indicating broader usage beyond later-stage patients. The company also highlighted that about 90% of covered lives are under plans with favorable RYTELO coverage policies, addressing previous concerns about reimbursement barriers.

Commercial Strategy

Geron outlined a three-pronged commercial strategy aimed at building on Q2’s momentum. The plan focuses on increasing healthcare provider awareness, improving prescribing confidence, and generating key opinion leader support.

The commercial plan of action includes specific initiatives as illustrated here:

The company is refining its prescriber targeting and has increased field sales headcount, with additional clinical educators to support physician education. Digital marketing campaigns and regional case study programs are being implemented to improve prescriber confidence. The presentation noted that Q2 2025 performance was achieved by the existing commercial team, suggesting potential for further growth as the expanded sales force becomes fully operational by year-end.

Medical (TASE:BLWV) Affairs Strategy

Complementing the commercial initiatives, Geron is significantly expanding its medical affairs capabilities to support RYTELO’s growth trajectory:

The medical affairs strategy mirrors the commercial approach with expanded Medical Liaison headcount aligned with sales regions and the addition of health economics and outcomes research (HEOR) leadership. The company is doubling its medical affairs headcount to support expanded key opinion leader engagement, education, and medical information dissemination—all critical elements for building physician confidence in a relatively new therapy.

Clinical Development Updates

Geron provided an encouraging update on its Phase 3 IMpactMF trial for relapsed/refractory myelofibrosis, a potential catalyst for future growth:

The trial has reached over 95% enrollment as of July 2025, with full enrollment expected by year-end. This positions the company for an interim analysis in the second half of 2026, with final analysis anticipated in the second half of 2028. The IMpactMF trial is significant as it’s the first trial evaluating overall survival as a primary endpoint in relapsed/refractory myelofibrosis, potentially differentiating RYTELO in an increasingly competitive market.

Financial Analysis

The financial overview revealed both strengths and ongoing challenges:

Geron reported a cash balance of $432.6 million as of June 30, 2025, representing a decrease from the $457.5 million reported at the end of Q1 2025. This continued cash burn reflects the significant investment in commercial infrastructure and ongoing clinical development. Q2 operating expenses totaled $61.5 million, with full-year 2025 expenses projected between $270 million and $285 million, consistent with previous guidance.

While the revenue growth is encouraging, the company’s cash burn rate remains a consideration for investors, particularly as Geron continues to invest heavily in commercial expansion and clinical development.

https://za.investing.com/news/company-news/geron-q2-2025-presentation-rytelo-sales-climb-24-stock-jumps-premarket-93CH-3822514

DHS Secretary Kristi Noem Reveals 80,000 Americans Applied To Become ICE Agents

 Homeland Security Secretary Kristi Noem told Fox News' Lawrence Jones that Immigration and Customs Enforcement (ICE) has received an overwhelming 80,000 applications for just 10,000 new jobs at the agency.

"Our recruitment efforts to hire 10,000 new ICE officers has been extremely successful. Lawrence, as of today, we have over 80,000 applicants for those ten thousand positions already," Noem said. 

She continued, "People and patriots across this country that say we want to join. We want to help and be a part of this effort. It's overwhelming to see the amount of response in support that our ICE officers have gotten." 

Perhaps the financial incentives, such as $50,000 signing bonus and tens of thousands in student loan repayment, were enough to drive the surge in applications. These benefits are clearly outlined on ICE's official website. 

Text from the website states: "America has been invaded by criminals and predators. We need YOU to get them out. You do not need an undergraduate degree." 

Democrats are going insane about ICE's messaging to bolster its forces - because just a few short years ago, these far-left lawmakers were trying to abolish the agency while facilitating the invasion of criminal illegal aliens.

Meanwhile, the official X account of South Park made things even more viral. 

One X user said, "When the government is funnier than you, time to retire." 

This all comes as anti-ICE attacks have skyrocketed by 830%, much of which has to do with Democrats and their dark-money billionaire-funded NGO network producing dangerous anti-ICE rhetoric. Read the latest report of an arson attack on an ICE building in Washington State.  

https://www.zerohedge.com/political/dhs-secretary-kristi-noem-reveals-80000-americans-applied-become-ice-agents

Trump, Putin To Meet As Soon As Next Week In Potential Breakthrough

 Update(1512ET): It appears the Wednesday Witkoff-Putin meeting in Moscow has led to a breakthrough of sorts, coming right down to the wire of threatened fresh US anti-Russia sanctions set to be imposed Friday. Presidents Trump and Putin plan to meet in person as soon as next week, the NY Times is reporting. A meeting with Ukraine's leader would then follow.

"President Trump intends to meet in person with President Vladimir V. Putin of Russia as soon as next week, and he plans to follow up shortly afterward with a meeting between himself, Mr. Putin and President Volodymyr Zelensky of Ukraine, according to two people familiar with the plan," the breaking report says.

There's as yet been no indicators from the Russian or Ukrainian sides of the plan. According to more details:

Mr. Trump disclosed his plans in a call with European leaders on Wednesday, the people said. The meetings would include only those three men, and would not include any European counterparts. The European leaders, who have tried to play a coordinating role on meetings to end the violence between Russia and Ukraine while supporting their European neighbor, appeared to accept what Mr. Trump said, one of the people familiar with the call said.

Anti-Moscow critics have said that the Kremlin is just buying more time with Washington while its military operations in Ukraine proceed at full pace. Will a breakthrough actually come of this? 

There must be something substantial cooking if both sides agree to a meeting, which would be the first such face-to-face interaction between Trump and Putin of the US president's second term.

* * * 

Bloomberg is reporting Wednesday that President Donald Trump suggested he would hike tariffs on more countries buying Russian energy, including China, as the deadline for ceasefire looms, and as US envoy Steve Witkoff is in Moscow trying to make headway with President Putin.

Witkoff's talks with Putin lasted three hours, according to Russian media, after Witkoff landed in the country early on Wednesday. Images in Russian media showed the two men smiling and shaking hands in an ornate, gilded hall - after having met for several rounds of meetings spanning prior months.

Getty Images

The Kremlin in follow-up called it "constructive and useful" - according to TASS. They discussed the ongoing war in Ukraine, RIA Novosti stated.

Last month, Trump's outlook turned more dire and negative on the chances for peace. "We thought we had [the war] settled numerous times, and then President Putin goes out and starts launching rockets into some city like Kyiv and kills a lot of people in a nursing home or whatever," he had said.

And last week witnessed the single deadliest airstrikes on Kiev since the war's start - with the death toll having risen to 32 after another man recently died of his injuries, following the collapse of a nine-story apartment that was struck.

Ukraine's Volodymyr Zelensky has of course welcomed the prospect tougher US sanctions and tariffs on nations buying Russian oil. He has made clear Ukraine's perspective that Putin would be forced into a serious peace deal if his war machine ran out of money.

Wednesday saw a fresh Russian attack in the central region of Zaporizhzhia, reportedly striking a holiday camp which left two dead and 12 wounded. "There's no military sense in this attack. It's just cruelty to scare people," Zelensky said in the aftermath.

As for the dialogue with Trump's envoy Witkoff, part of it took place through conversation with Putin’s economic envoy Kirill Dmitriev, with the two taking a relaxed stroll through a public park in Moscow, which apparently caught some random Muscovites by surprise.

So the Kremlin appears to be sending calm messaging, likely in hopes that Trump will hold off on implementing the more dire and drastic of consequences and threats.

Dmitriev has at the same time said he is confident Moscow and Washington can find common ground through diplomacy and honest dialogue. The CEO of the Russian Direct Investment Fund (RDIF) took to X after the Witkoff meeting and thanked his followers in English for "kind wishes for a successful visit of Steve Witkoff to Moscow," adding that "Dialogue will prevail."

Will it? Let's hope so.

https://www.zerohedge.com/geopolitical/dialogue-will-prevail-unexpected-scenes-witkoff-putin-envoy-strolling-through-moscow

Goldman Sachs Says US Yield-Curve Shape Looks Like Zero-Rate Era

 


US Treasury debt maturing in five years has rarely been this expensive relative to other maturities except when the Federal Reserve has dropped interest rates to zero, according to interest-rate strategists at Goldman Sachs.

The five-year Treasury yield at around 3.78% Wednesday remains near the high end of its range since early 2022 — the last time the low end of the Fed’s target for the US overnight lending rate was 0%. But a common relative-value calculation for bonds — in which a yield is evaluated relative to a pair of shorter- and longer-maturity tenors — shows the five-year is historically rich.

https://www.bloomberg.com/news/articles/2025-08-06/goldman-sachs-says-us-yield-curve-shape-looks-like-zero-rate-era